Pediatric intracranial dural arteriovenous fistulas: age-related differences in clinical features, angioarchitecture, and treatment outcomes

Steven W. Hetts, MD; Parham Moftakhar, MD; Neil Maluste, MD; Heather J. Fullerton, MD, MAS; Daniel L. Cooke, MD; Matthew R. Amans, MD, MS; Christopher F. Dowd, MD; Randall T. Higashida, MD, and Van V. Halbach, MD

OBJECTIVE Intracranial dural arteriovenous fistulas (DAVFs) are rare in children. This study sought to better characterize DAVF presentation, angioarchitecture, and treatment outcomes.

METHODS Children with intracranial DAVFs between 1986 and 2013 were retrospectively identified from the neurointerventional database at the authors’ institution. Demographics, clinical presentation, lesion angioarchitecture, treatment approaches, angiographic outcomes, and clinical outcomes were assessed.

RESULTS DAVFs constituted 5.7% (22/423) of pediatric intracranial arteriovenous shunting lesions. Twelve boys and 10 girls presented between 1 day and 18 years of age; boys presented at a median of 1.3 years and girls presented at a median of 4.9 years. Four of 8 patients ≤ 1 year of age presented with congestive heart failure compared with 0/14 patients > 1 year of age (p = 0.01). Five of 8 patients ≤ 1 year old presented with respiratory distress compared with 0/14 patients > 1 year old (p = 0.0021). Ten of 14 patients > 1 year old presented with focal neurological deficits compared with 0/8 patients ≤ 1 year old (p = 0.0017). At initial angiography, 16 patients harbored a single intracranial DAVF and 6 patients had 2–6 DAVFs. Eight patients (38%) experienced DAVF obliteration by the end of treatment. Good clinical outcome (modified Rankin Scale score 0–2) was documented in 77% of patients > 1 year old at presentation compared with 57% of patients ≤ 1 year old at presentation. Six patients (27%) died.

CONCLUSIONS Young children with DAVFs presented predominantly with cardiopulmonary symptoms, while older children presented with focal neurological deficits. Compared with other pediatric vascular shunts, DAVFs had lower rates of angiographic obliteration and poorer clinical outcomes.

http://thejns.org/doi/abs/10.3171/2016.5.PEDS15740

KEY WORDS dural arteriovenous fistula; DAVF; vascular disorders; neurological deficit; cardiopulmonary
Finally, we compare the outcomes of children with DAVFs with other pediatric intracranial arteriovenous shunts.

**Methods**

**Study Cohort**

In this institutional review board–approved study, a neurointerventional database was used to identify a cohort of 423 patients ≤18 years of age who had undergone evaluation and treatment for intracranial arteriovenous shunts at our hospital between 1986 and 2013. Medical records and imaging reports were reviewed. Forty patients with potential DAVFs were identified. Patients who developed DAVFs subsequent to treatment of another primary intracranial arteriovenous shunting lesion (e.g., non-Galenic pial arteriovenous fistula [NGAVF] or arteriovenous malformation [AVM]) were excluded. After further review of reports, the cohort was reduced to 24 patients with primary intracranial DAVFs. Of these 24 patients, 2 were excluded due to insufficient clinical or imaging data.

**Medical Record Review**

Baseline clinical presentation data were collected for each subject (Supplemental Table 1). Arterial and venous angioarchitectural characteristics identified from initial pretreatment angiograms were also documented (Supplemental Tables 2 and 3).

**Imaging Review**

Baseline cerebral digital subtraction angiograms (DSAs) with corresponding reports were available for 20 of 22 patients. Angiographic images were reviewed and scored (by S.W.H., N.M., and P.M.) according to a structured angiographic data collection tool originally developed for brain AVMs and subsequently modified to highlight features specific to DAVFs. If discrepancies between angiographic images and reports were discovered, images were reviewed and results derived from image review were used for final scoring. Two patients were scored from structured angiographic reports alone due to an inability to retrieve old images. These reports are of the same format and were authored by the same group of angiographers present for the entire study period. To exclude potential bias from inclusion of the aforementioned 2 patients, we performed a sensitivity analysis on data excluding these patients and did not find significant changes in effect sizes (data not shown).
DAVs were categorized into those with single arteriovenous connections and those with multiple arteriovenous connections. Venous sinus dilation was defined as twice the expected diameter of a given dural venous sinus based on angiograms performed at our institution of children of similar ages but without arteriovenous shunting. Venous reflux was defined as any abnormal reversal of blood flow within cerebral veins or venous sinuses on DSAs. Pseudo-phlebitic cortical venous pattern was defined as tortuous, engorged pial veins noted during the venous phase of digital subtraction angiography.

**Treatment**

Patients were managed with conservative observation, endovascular intervention, a combination of endovascular and surgical intervention, or a combination of endovascular and radiosurgical intervention. Treatment and outcome data are detailed in Supplemental Table 4.

**Outcomes**

Two investigators (S.W.H. and N.M.) reviewed medical records from each patient’s last available clinical follow-up evaluation to assess neurological status and developmental disability; any disagreements were resolved via further review and consensus. An adapted modified Rankin Scale (mRS) score of neurological disability for pediatric patients with brain AVMs was used to retrospectively assign each patient both baseline clinical function and final clinical function. Good clinical outcome was defined as pediatric mRS scores of 0–2. Images and imaging reports from each patient’s last follow-up were evaluated for residual arteriovenous shunting or new DAVF formation. Follow-up duration was calculated from initial clinical presentation to final clinical or imaging report.

**Statistical Analysis**

Our cohort of patients was stratified both by sex and age at presentation: neonates and infants presenting at ≤ 1 year of age compared with older children presenting at > 1 year of age (Tables 1 and 2). Student t-tests were used to compare continuous normally distributed data, Wilcoxon rank-sum (Mann-Whitney) tests were used to compare ordinal data, and Fisher’s exact tests were used to compare proportions. Descriptive statistics and t-tests were calculated using Excel for Macintosh 2011 (Microsoft). Odds ratios (ORs), confidence intervals (CIs), Fisher’s exact tests, and Wilcoxon rank-sum tests were calculated using Stata SE (version 12.1, StataCorp).

**TABLE 2. Treatments and outcomes stratified by age at presentation**

<table>
<thead>
<tr>
<th>Treatments</th>
<th>All Patients</th>
<th>Age ≤1 Yr</th>
<th>Age &gt;1 Yr</th>
<th>OR</th>
<th>95% CI</th>
<th>p Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at first treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>6.8 ± 7.7 yrs</td>
<td>108 ± 122 days</td>
<td>10.5 ± 7.4 yrs</td>
<td></td>
<td></td>
<td>0.0009</td>
</tr>
<tr>
<td>Median</td>
<td>1.7 yrs</td>
<td>92 days</td>
<td>11.6 yrs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>1 day–18.9 yrs</td>
<td>1 day–353 days</td>
<td>1.2–18.9 yrs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median Dx or Tx procedures (range)</td>
<td>2 (1–19)</td>
<td>1 (1–5)</td>
<td>2 (1–19)</td>
<td></td>
<td></td>
<td>0.42†</td>
</tr>
<tr>
<td>Median treatment procedures (range)</td>
<td>1 (0–18)</td>
<td>1 (0–5)</td>
<td>2 (1–18)</td>
<td></td>
<td></td>
<td>0.22†</td>
</tr>
<tr>
<td>Endovascular treatments only</td>
<td>14/21 (67%)</td>
<td>5/8 (63%)</td>
<td>9/13 (69%)</td>
<td>0.74</td>
<td>0.83–7.3</td>
<td>1</td>
</tr>
<tr>
<td>Any open surgical treatment</td>
<td>4/21 (19%)</td>
<td>1/8 (13%)</td>
<td>3/13 (23%)</td>
<td>0.48</td>
<td>0.0080–7.7</td>
<td>1</td>
</tr>
<tr>
<td>Any stereotactic radiosurgery</td>
<td>2/21 (10%)</td>
<td>0/8 (0%)</td>
<td>2/13 (15%)</td>
<td>0</td>
<td>0–3.2</td>
<td>0.5</td>
</tr>
<tr>
<td>Observation only</td>
<td>2/21 (10%)</td>
<td>2/8 (25%)</td>
<td>0/13 (0%)</td>
<td>Inf</td>
<td>0.93–inf</td>
<td>0.13</td>
</tr>
<tr>
<td>Procedural or periprocedural complication</td>
<td>4/21 (19%)</td>
<td>1/8 (13%)</td>
<td>3/13 (23%)</td>
<td>0.48</td>
<td>0.0080–7.7</td>
<td>1</td>
</tr>
<tr>
<td>Follow-up duration‡</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>5.5 ± 6.3 yrs</td>
<td>3.5 ± 5.7 yrs</td>
<td>6.4 ± 6.5 yrs</td>
<td></td>
<td></td>
<td>0.37</td>
</tr>
<tr>
<td>Median</td>
<td>3.6 yrs</td>
<td>186 days</td>
<td>6.1 yrs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>2 days–23.1 yrs</td>
<td>2 days–14.2 yrs</td>
<td>180 days–23.1 yrs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elimination of all arteriovenous shunting</td>
<td>8/21 (38%)</td>
<td>3/8 (38%)</td>
<td>5/13 (38%)</td>
<td>1</td>
<td>0.12–8.9</td>
<td>1</td>
</tr>
<tr>
<td>White matter calcifications‡</td>
<td>2/11 (18%)</td>
<td>0/5 (0%)</td>
<td>2/6 (33%)</td>
<td>0</td>
<td>0–2.2</td>
<td>0.45</td>
</tr>
<tr>
<td>Normal neurological examination¶</td>
<td>6/16 (38%)</td>
<td>1/5 (20%)</td>
<td>5/11 (45%)</td>
<td>0.3</td>
<td>0.0051–4.9</td>
<td>0.59</td>
</tr>
<tr>
<td>Deceased after discharge for any reason</td>
<td>6/22 (27%)</td>
<td>2/8 (25%)</td>
<td>4/14 (29%)</td>
<td>0.83</td>
<td>0.059–8.2</td>
<td>1</td>
</tr>
<tr>
<td>Median last mRS score (range)**</td>
<td>1 (0–6)</td>
<td>1 (0–6)</td>
<td>1 (0–6)</td>
<td></td>
<td></td>
<td>0.53†</td>
</tr>
<tr>
<td>Good outcome (last mRS score 0–2)**</td>
<td>14/20 (70%)</td>
<td>4/7 (57%)</td>
<td>10/13 (77%)</td>
<td>0.4</td>
<td>0.037–4.5</td>
<td>0.61</td>
</tr>
</tbody>
</table>

Dx = diagnostic, Tx = therapeutic.
* p values are derived from Fisher’s exact test unless otherwise specified.
† Wilcoxon log rank-sum test.
‡ Data available for 18/22 patients.
§ Data available for 11/22 patients.
¶ Data available for 16/22 patients.
** Data available for 20/22 patients.
Results

Demographic Information

DAVFs were present in 5.7% (244/423) of the pediatric patients evaluated and treated for intracranial arteriovenous shunts at our hospital during the study period. Of the 22 patients included for further analysis, 8 presented at ≤ 1 year of age and 14 presented at > 1 year of age (median age 1.7 years, range 1 day to 18.9 years; Table 1). Whereas 12 boys presented at a median age of 1.3 years, 10 girls presented at a median of 4.9 years. Detailed baseline demographics and clinical presentations are summarized in Supplemental Table 1.

Clinical Presentation

Clinical presentation varied by age (Table 1) but was not significantly different between boys and girls. One boy was suspected to have an intracranial arteriovenous fistula on fetal MRI in the setting of hydrops fetalis. Three patients presented as neonates (<1 month), 5 patients presented in later infancy (3 months to 1 year), and 14 patients presented later in childhood (1.2–18 years).

Neonates presented with congestive heart failure (CHF; 3/3), respiratory distress (2/3), and hydrocephalus (3/3). Aside from hypotonia (3/3), neurological deficits were not apparent in this very young group. No intracranial hemorrhages were identified in this group. Of 5 patients who presented between 1 month and 1 year of age, 3 had respiratory distress, 3 had hydrocephalus or macrocephaly, 2 had facial or cranial hemangiomas or venous or lymphatic malformations, 1 had seizures, 1 had developmental delay, and 2 had intracranial hemorrhage.

Of 14 patients who presented after the first year of life, clinically 2 children presented with headaches, 2 demonstrated developmental delay, 2 presented with intracranial hemorrhage, and 3 children presented with carotid cavernous fistulas following trauma. On examination, 10 presented with focal neurological deficits (cranial nerve palsies, aphasia, hemiparesis, axial weakness, facial droop, and ophthalmoplegia), 6 had cranial bruits, 2 demonstrated head and neck hemangiomas or venous or lymphatic malformations, and 1 child had macrocephaly with hydrocephalus.

Potential risk factors for intracranial DAVFs as well as comorbidities associated with significant arteriovenous shunting were identified in multiple patients. One patient had hydrops fetalis due to severe arteriovenous shunting. Obstetric complications that may have contributed to fetal CHF included maternal diabetes mellitus Type 2 and placental abruption. One patient had Cowden syndrome.

Several patients possessed congenital vascular anomalies including a forehead angioma, eyelid and scalp hemangiomas, a lymphatic malformation of the neck and tongue, and a port wine stain.

Angioarchitecture

DAVF angioarchitecture in our cohort did not vary significantly between different age groups (Table 1). Identification of multiple DAVFs (between 2 and 6) in a single patient occurred in 29% of the patients > 1 year old versus 13% of patients ≤ 1 year old (p = 0.61). Both age groups demonstrated similar proportions of patients with complex DAVFs possessing more than 1 arteriovenous connection. Common DAVF locations included the torcular (n = 9), transverse sinus (n = 7), superior sagittal sinus (SSS; n = 6), and cavernous sinus (n = 6). With regard to vascular sequelae of dural arteriovenous shunting, venous sinus dilatation trended toward occurring more frequently in younger children (75% vs 43%, respectively; p = 0.2) but both age groups possessed similar percentages of patients with venous ectasia, venous reflux, and venous sinus thrombosis. A pseudophlebitic cortical venous pattern secondary to venous congestion was observed more commonly in patients > 1 year of age (50%) as compared with patients ≤ 1 year of age (13%; p = 0.17). Significant differences in DAVF angioarchitecture were not observed between the male and female patients, although there was a trend toward venous reflux occurring more commonly in girls (p = 0.2).

Treatment

Treatments, imaging outcomes, clinical outcomes, and procedural complications are detailed in Table 2 and Supplemental Table 4. Patients received between 1 and 19 endovascular, radiosurgical, or surgical procedures with a median of 2 interventions. Sixty-seven percent of our patients received endovascular treatment only. Patients presenting at > 1 year of age trended toward more treatments than patients presenting at ≤ 1 year (median 2 vs median 1, p = 0.22).

Twenty-one of 22 patients had sufficient data available at our institution with regard to DAVF treatment and were further analyzed. Transvenous and transarterial endovascular treatments employed a variety of materials: coils, 11/21 patients (52%); particulate embolics, 8/21 patients (38%); liquid adhesives, 8/21 patients (38%); absolute ethanol, 3/21 patients (14%); detachable balloons, 3/21 patients (14%); and silk sutures, 1/21 patients (5%). Four patients (19%) underwent craniotomy and resection and 2 patients...
DAVs are defined by an aberrant connection between a dural artery and either a dural venous sinus or cortical vein. The complexity of these lesions can vary substantially, with some DAVFs having only a single arteriovenous connection and others having numerous arteriovenous connections. Although pediatric DAVFs may arise early in utero, analogous to a vein of Galen malformation (VOGM), some of these lesions appear to be acquired later in development or postnatally. The presence of mature arterial and venous architecture in most DAVFs, for example, suggests that DAVFs are most likely acquired at some point following the third month of intrauterine life. Massive venous sinus enlargement is a hallmark of congenital DAVFs not observed in adult-acquired DAVFs, underscoring their origins in the fetus wherein sinuses are normally large and may remain large due to high fistulous flow, instead of regressing. It is theorized that venous thrombosis during fetal life promotes the formation of 1 or more DAVFs prior to birth, analogous to venous sinus thrombosis in adults leading to DAVF formation. Postnatally, however, thrombocytopenia due to platelet consumption along the surface of huge clots in enlarged venous sinuses can complicate DAVF treatment.

There are two major hypotheses explaining the pathogenesis of DAVFs. One hypothesizes that DAVFs arise from “dormant” channels between the external carotid circulation and the venous pathways within the dura mater that open in response to venous hypertension. The other suggests that new vascular channels are stimulated by angiogenic factors that arise directly from sinus thrombosis or as a result of tissue hypoxia. Although the etiology of DAVFs remains to be elucidated, it is likely that the combination of arterialized turbulent blood, progressive venous sinuses hypertensive, and venous reflux results in progressive veno-occlusive disease that can lead to the melting brain syndrome, as noted in several of our patients (Fig. 1). In the melting brain syndrome, chronic venous hypertension leads to irreversible brain injury with white matter calcifications and encephalomalacia. Usually bilateral and symmetric, melting brain syndrome corresponds to a regional decrease in cerebral blood flow caused by the retrograde venous hypertension.

Risk factors for development of DAVFs may be genetic or environmental. Some arteriovenous shunts have been linked to chromosomal abnormalities, including hemorhagic hereditary telangiectasia and neurofibromatosis Type 1 (as in Case 7 in our cohort; Supplemental Table 1). Many of our patients with DAVFs also presented with peripheral hemangiomas or venous or lymphatic malformations. Hypercoagulable states are also a risk factor for sinus thrombosis and subsequent formation of DAVFs, including leukemia (Case 17, Fig. 2; Supplemental Table 1) and smoking. Trauma—as in Cases 18, 20, and 22—is another well-known risk factor for the development of DAVFs.

We identified 24 patients with imaging-confirmed DAVFs from a cohort of 423 patients with intracranial arteriovenous shunts, for a total incidence of 5.7%. This is lower than the incidence of approximately 10% reported by Garcia-Monaco et al. The true incidence of this rare disease is unknown. Five (23%) of 22 patients in our cohort had multiple separate (multifocal) DAVFs as compared with 3.5% of patients in the Garcia-Monaco
In contrast to the Kincaid et al. and Garcia-Monaco DAVF series, in our study multifocal DAVFs were observed more often in patients > 1 year of age at presentation as compared with patients ≤ 1 year of age. Some of this may be due to the high complexity and size of the neonatal DAVFs in our series. For example, in Case 3 (Supplemental Table 2), it was difficult to judge whether that patient had a single large torcular DAVF or instead had adjacent but separate torcular and superior vermian DAVFs.

Our data suggest that neonates and infants up to 1 year of age predominantly present with cardiorespiratory symptoms from high-output arteriovenous shunting and undershunting due to intracranial venous hypertension. Older patients tended to present with neurological symptoms as opposed to cardiorespiratory symptoms. Younger children more commonly presenting with CHF, respiratory distress, and hydrocephalus, and older children more commonly presenting with focal neurological deficits is consistent with other pediatric DAVF series and also parallels the clinical presentations in NGAVF and VOGM. As with adults, the most predictive feature for future neurological manifestations was the presence or absence of cerebral venous reflux. In our analysis, more than half of patients with venous reflux had poor outcomes. All patients without venous reflux had good outcomes.

With regard to DAVF location, our results were similar to those in other major series with the most common sites being the torcular, SSS, transverse sinus, and cavernous sinus (Fig. 3). DAVFs away from the torcular should theoretically have a better chance of favorable outcomes, as there will be at least 1 normal sinus for the brain to drain. In our series, 43% of patients with torcular involvement had poor outcomes.

Multiple classification systems exist for pediatric DAVFs. Lasjaunias’ classification system included 3 types of shunts, including the dural sinus malformation (DSM), infantile-type DAVFs, and adult-type DAVFs. DSMs can further be subdivided into 2 types. The first type of DSM involves the posterior sinus with or without the torcular, with giant dural lakes and slow-flow mural arteriovenous shunting. Spontaneous thrombosis may further restrict cerebral venous drainage and subsequently lead to intraparenchymal hemorrhagic infarction. The second type of DSM involves the jugular bulb with otherwise normal sinuses but associated with a high-flow sigmoid sinus AVF. The prognosis is excellent with embolization treatment.

In our series, there were 4 patients with DSMs, 2 died during the study, and 2 met their respective developmental milestones (ages 4 months and 16 years).

Infantile dural arteriovenous shunts are high flow and low pressure. The sinuses are large and patent with no lakes. Clinical onset is observed in the first few years of life and the shunts are initially well tolerated. Progressive symptoms (symptoms of raised intracranial pressure and venous ischemia) develop at a later age and initially re-
spond to partial embolization. The long-term prognosis is poor with neurological deterioration in early adulthood.24 In our series, there were a total of 6 patients with infantile-type DA VFs (1 child demonstrating both infantile- and adult-type fistulas). On last follow-up only 1 child was meeting their developmental milestones. Two of the children were deceased, 1 had a poor neurological examination result, and the other 2 required special assistance.

Adult-type DA VFs are present in all age groups and almost all of them are located in the cavernous venous plexus. Post-embolization outcome is excellent.24 In our series, 10 patients demonstrated adult-type DA VFs and all but 1 were meeting their respective developmental milestones (1 child was deceased due to leukemia).

Endovascular intervention is the mainstay of DAVF treatment.21 Surgery and radiosurgery are usually reserved for cases in which endovascular therapy fails or is not possible due to difficult access to the fistula site. We favor the use of coils to treat DA VFs in young children over the use of liquid embolic agents, given the potential for nontarget embolization of liquid embolics to the lung or elsewhere. Close collaboration with pediatric cardiology is essential, not only for evaluation of right-to-left shunting, raising the potential for systemic nontarget embolization, but also for evaluation of DAVF treatment effect on CHF. Nontarget embolization of liquid embolic agents in neonates and infants, especially in the setting of CHF, can be clinically devastating. Nontarget embolization of coils to the lungs can also occur, but coils are potentially retrievable. In some cases performing embolization solely with coils is
unrealistic and a combination of coils and liquid embolic agents are needed to stop flow at the fistulous point. With the introduction of ethylene vinyl copolymer, several reports both in children and adults have demonstrated successful results with acceptable complication rates.\textsuperscript{5,21} The relatively long time over which ethylene vinyl copolymer is deposited, however, leads to relatively high fluoroscopy-related x-ray doses.

Despite advances in embolization techniques, endovascular treatment of pediatric DAVFs remains challenging. The neurointerventionalist must account for the presence of high-flow fistulas, tortuous intracranial feeding arteries, a small femoral artery access site, limitations in the volume of contrast, and risk of general anesthesia in a critically ill neonate. Due to small total blood volumes and coexistent CHF, surgery is also risky in neonates. Stereotactic radiosurgery has limited ability to induce regression of large caliber fistulas, and from a practical standpoint, frame placement is not possible in young patients with open cranial sutures. Our overall approach for the treatment of DAVFs is similar to our approach to other pediatric vascular shunts (NGAVFs, VOGMs).\textsuperscript{8,23} We favor delaying treatment until after the first several months of life unless CHF or signs of venous hypertension necessitate early intervention. Due to the significant morbidity and mortality associated with these lesions and possibility of recruitment of secondary shunts, our goal is to eradicate the fistula site. However, as noted by Kincaid et al.,\textsuperscript{21} complex multifocal dural shunts cannot be immediately cured by current embolization techniques because complete occlusion of all the involved sinuses would result in severe venous outflow restriction. In patients with complex multifocal DAVFs, endovascular treatment is staged with periods of observation generally aimed at symptomatic relief.

At the last clinical or imaging follow-up evaluation, 8/21 patients (38%) in our cohort demonstrated complete elimination of arteriovenous shunting, 7/20 (35%) had no neurological deficit or developmental delay, and 6/22 patients (27%) were deceased. Kincaid et al.\textsuperscript{21} reported elimination of arteriovenous shunting in 3/7 patients (43%), no neurological deficit or developmental delay in 2/7 patients (29%), and death in 2/7 patients (29%). On the other hand, Walcott et al.\textsuperscript{33} reported elimination of arteriovenous shunting in nearly all their patients (6/7, 86%), no neurological deficit or developmental delay in any of their patients (7/7, 100%), and no deaths (Table 3). Treatment in the Kincaid et al. and Walcott et al. series was almost exclusively endovascular, with 1 exception in the Walcott et al. series that used combined endovascular/surgical treatment. The Walcott et al. study concluded that treatment is effective in the obliteration of DAVFs in children and is well tolerated, with patients having excellent prognoses. Most of the children in that series were older and were stable clinically on presentation. Our study and the Kincaid group, however, include more neonates and infants who were less stable clinically on presentation. Furthermore, the Walcott et al. study did not report the complexity and angiography of their DAVFs, making direct comparisons difficult. The similarity between results from our center and the Kincaid group suggests that DAVF remains a challenging diagnosis to treat in children. In their long-term experience with pediatric DAVFs, Lasjaunias et al.\textsuperscript{25} noted that some DAVFs are lethal even 10 years after onset, indicating the caution with which we must approach our decisions. Long-term follow-up should contextualize optimistic case reports about these lesions.\textsuperscript{25}

Compared with other pediatric intracranial AVF patient groups studied at our institution, our DAVF cohort had lower rates of complete AVF occlusion, lower rates of children with no neurological deficit or developmental delay at last clinical follow-up, and higher rates of death at last known follow-up (Table 4).\textsuperscript{4,37} It is also sobering to note that patients with DAVFs presenting in childhood are more likely to have de novo formation of additional DAVFs later in life.\textsuperscript{18}

**Conclusions**

Similar to other intracranial arteriovenous shunting lesions in children, DAVFs are more likely to present with cardiorespiratory distress and hydrocephalus in neonates and infants ≤ 1 year of age and with focal neurological deficits in patients > 1 year of age. Given the complex angioarchitecture of these lesions, morbidity of these lesions remains high. Long-term outcomes are generally worse for children with DAVFs as compared with other types of intracranial arteriovenous fistulas. If symptomatic, treatment appears warranted to prevent the long-term sequelae of venous hypertension.

**Acknowledgments**

This study was supported by NIH T32 training grant no. NIBIB T32 EB001631 to Dr. Moftakhar.

**References**


J. Neurosurg Pediatrics Volume 18 • November 2016

---

**Notes**

- **Endovascular Treatment**: Ethylene vinyl copolymer is effective in the obliteration of DAVFs in children and is well tolerated, with patients having excellent prognoses.
- **Clinical Outcomes**: The Walcott et al. study reported higher rates of complete occlusion and lower rates of death compared to the Kincaid et al. study.
- **Complex Lesions**: Multifocal dural shunts are more challenging to treat due to their complex angioarchitecture.
- **Future Directions**: Long-term follow-up is crucial to understand the outcomes and potential long-term sequelae of venous hypertension.


**Disclosures**

Dr. Hetts has served as a consultant to Stryker Neurovascular and Neuravi, has direct stock ownership in Medina Medical, is a patent holder for an invention licensed to Penumbra, and has received research contracts for evaluation of imaging equipment (Siemens) or for provision of core angiography lab facilities for clinical trials not related to the work under consideration from MicroVention Terumo and Stryker Neurovascular.

**Author Contributions**

Conception and design: Hetts. Acquisition of data: Hetts, Moftakhar, Maluste, Dowd. Analysis and interpretation of data: Hetts, Moftakhar, Maluste, Dowd. Drafting the article: Moftakhar. Critically revising the article: Hetts, Fullerton, Cooke, Higashida, Halbach. Reviewed submitted version of manuscript: Hetts, Fullerton, Cooke, Amans, Dowd, Higashida, Halbach. Approved the final version of the manuscript on behalf of all authors: Hetts. Statistical analysis: Hetts. Study supervision: Dowd, Halbach.

**Supplemental Information**

Online-Only Content

Supplemental material is available with the online version of the article. *Supplemental Tables 1–4. http://thejns.org/doi/suppl/10.3171/2016.5.PEDS15740.*

**Correspondence**

Steven W. Hetts, Neurointerventional Radiology, University of California, San Francisco, 505 Parnassus Ave., L-352, San Francisco, CA 94143-0628. email: steven.hetts@ucsf.edu.